Drug Trial Radar · NCT04826107
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
196
Planned (sponsor's estimate)
Start
Aug 2021
Primary completion
Aug 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.
Conditions
- Gastric Cancer
Interventions
DP303c treatmentDrug
DP303c injection, every 3 weeks.
DP303c treatment(second-line of HER2-positive)Drug
DP303c injection, every 3 weeks.
DP303c treatment (third-line of HER2-positive)Drug
DP303c injection, every 3 weeks.
DP303c treatment(≥second-line of HER2 low expressing)Drug
DP303c injection, every 3 weeks.
DP303c + PD-1/PD-L1 treatmentDrug
DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR(Objective Response Rate)Time frame: Up to 2.5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.